30 May 2025
Orbis Diagnostics is transforming blood testing from its base in Aotearoa New Zealand. Their mission: make lab-quality blood tests fast, easy, and accessible anywhere—starting with a single drop from a fingerstick. Think the simplicity of a Nespresso machine, but for diagnostics.
At the heart of Orbis’ story is a bold vision for decentralised healthcare. With 70% of all medical decisions driven by blood test data, the ability to bring accurate testing directly to consumers promises to ease pressure on doctors, hospitals, and pharmacies worldwide. Their technology empowers people to take control of their health—changing the world one drop at a time.
Their first diagnostic panel focuses on Hepatitis B, a virus that has infected over 2 billion people and causes half of all liver cancer cases. There’s no cure, but early detection helps. In response to a 2023 CDC call for universal screening, Orbis has developed the world’s first point-of-care test that checks all three required blood markers—in just 30 minutes—with lab-level accuracy.
Now, the company is in the midst of a USD $5 million capital raise to finalise engineering product development, build prototypes, and complete a design freeze. This will set the stage for a USD $30 million raise in 2026, following a pivotal US-based clinical trial. The innovation engine, however, will remain firmly rooted in New Zealand, where the team will continue developing a pipeline of diagnostic panels—including a broader liver cancer panel and up to six additional panels over the next two years.
With existing investors reinvesting and international interest growing, Orbis is actively seeking a lead investor to anchor this raise. Time spent in the US by the executive team—attending conferences and meeting face-to-face with investors and partners—has already proven transformative, reinforcing the value of global connection alongside local innovation.
Find out more at: https://www.orbisdiagnostics.com/